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ABSTRACT 
BACKGROUND & AIMS: Standardized instruments are needed to assess the activity of 
eosinophilic esophagitis (EoE), to provide endpoints for clinical trials and observational 
studies. We aimed to develop and validate a patient-reported outcome (PRO) instrument 
and score, based on items that could account for variations in patients’ assessments of 
disease severity. We also evaluated relationships between patients’ assessment of disease 
severity and EoE-associated endoscopic, histologic, and laboratory findings.  
METHODS: We collected information from 186 patients with EoE in Switzerland and the US 
(69.4% male; median age, 43 years) via surveys (n = 135), focus groups (n = 27), and semi-
structured interviews (n = 24). Items were generated for the instruments to assess biologic 
activity based on physician input. Linear regression was used to quantify the extent to which 
variations in patient-reported disease characteristics could account for variations in patients’ 
assessment of EoE severity. The PRO instrument was prospectively used in 153 adult 
patients with EoE (72.5% male; median age, 38 years), and validated in an independent 
group of 120 patients with EoE (60.8% male; median age, 40.5 years). 
RESULTS: Seven PRO factors that are used to assess characteristics of dysphagia, 
behavioral adaptations to living with dysphagia, and pain while swallowing accounted for 
67% of the variation in patients’ assessment of disease severity. Based on statistical 
consideration and patient input, a 7-day recall period was selected. Highly active EoE, based 
on endoscopic and histologic findings, was associated with an increase in patient-assessed 
disease severity. In the validation study, the mean difference between patient assessment of 
EoE severity and PRO score was 0.13 (on a scale from 0 to 10). 
CONCLUSIONS: We developed and validated an EoE scoring system based on 7 PRO 
items that assesses symptoms over a 7-day recall period. Clinicaltrials.gov number: 
NCT00939263. 
 
KEYWORDS: disease activity measurement, esophagus, patient reported outcome, marker  
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INTRODUCTION 
     Eosinophilic esophagitis (EoE) is a young disease, as only a little more than two decades 
have passed, since this condition has been recognized as its own standing entity.1,2 Some 
years ago, a panel of international experts defined EoE as “a chronic, immune/antigen-
mediated, esophageal disease characterized clinically by symptoms related to esophageal 
dysfunction and histologically by eosinophil-predominant inflammation”.3 The prevalence of 
EoE is currently estimated at 1/2,000 in the pediatric and adult population of the United 
States and Europe.4,5,6,7 Most adult patients suffer from dysphagia. However, patients may 
also report refractory heartburn and/or chest pain, which is centrally located and does not 
adequately respond to acid-suppressive medications.8,9,10 
     A standardized and validated patient-reported outcome (PRO) instrument assessing 
symptom severity in patients with EoE is urgently needed to define meaningful endpoints for 
clinical trials and to follow disease evolution in observational studies. Until now, EoE 
symptoms in adult patients have been evaluated in clinical trials using different PRO 
instruments. For example, Alexander et al. used the Mayo Dysphagia Questionnaire 30-Day 
(MDQ-30) version and found that swallowed fluticasone improved histologic characteristics, 
but not symptoms of EoE in adult patients.11 The MDQ-30 version has been validated in a 
group of patients presenting with dysphagia and thoracic pain due to various gastrointestinal 
diseases, but not specifically due to EoE.12 An ad hoc-constructed symptom assessment 
instrument was used by Straumann et al. in a placebo controlled study to evaluate the 
efficacy of budesonide in adult EoE patients.13,14 Dellon et al. developed the dysphagia 
symptom questionnaire (DSQ), a 3-item electronic PRO administered daily to assess the 
frequency of dysphagia caused by eating solid food and relief strategies during the 
dysphagia episodes.15 This DSQ was evaluated in a group of 35 adolescent and adult EoE 
patients with clinically and histologically active disease.15 Of note, none of these three 
instruments fulfill all the criteria currently required for an EoE PRO instrument. The 
assessment of dysphagia is particularly challenging, as it depends not only on disease 
severity, but also on consistencies of foods consumed, and on behavioral adaptation 
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strategies to living with dysphagia. Thus, any PRO instrument assessing dysphagia must 
take these factors into account.  
     Given the lack of standardized, validated PRO instruments, the results of clinical trials 
performed in EoE cannot be easily compared. This might also explain why different 
therapeutic trials document various degrees of association between patient-reported 
symptoms and endoscopic and histologic findings.11,13,14 The current situation poses a major 
challenge for regulatory approval of EoE therapies.16,17 
     In this paper, we describe the process of development and validation of a PRO 
instrument for adult EoE patients. The study was carried out in accordance with the US Food 
and Drug Administration (FDA) guidelines.16 
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PATIENTS AND METHODS 
Study overview 
     The adult EEsAI study was carried out in three phases, which are illustrated in 
supplementary Figure 5. During the 1st phase, a comprehensive list of relevant items to be 
potentially incorporated into the PRO, endoscopy, histology, and blood biomarker 
instruments was generated. During the 2nd phase, the prototypes of standardized 
instruments were evaluated in a first patient group. Data derived from the PRO instrument 
were used to derive a symptom severity score. During the 3rd phase, the PRO instrument 
and PRO score were validated in a second group of adult EoE patients. 
Item generation 
     We first established a conceptual framework for instruments to assess symptoms, 
behavioral adaptations, and biologic activity of adult EoE patients (Figure 1). For the item 
generation, a review of the literature and the existing instruments to assess clinical, 
endoscopic, histologic, and biochemical EoE activity was carried out, and expert opinion was 
provided using the Delphi technique (telephone conferences and emails). The Delphi 
technique allows geographically dispersed experts to reach a consensus on a particular 
complex task.18 A Delphi group of adult EoE gastroenterologists (N = 9), allergists (N = 2), 
and pathologists (N = 2) from Switzerland and the United States contributed a list of items 
that they thought best in reflecting endoscopic [N = 6 items], histologic [N = 7 items], and 
biochemical activity [N = 5 items]). 
     For the PRO instrument item generation, patient input was obtained by a mixed methods 
approach using open-ended patient symptom surveys (N = 135 patients), focus groups (N 
= 27 patients) as well as semistructured patient interviews (N = 24 patients). The 
qualitative methods of the development of the PRO instrument are described in detail in the 
supplementary section (Appendix 1 includes supplementary Tables 1 to 8 and 
supplementary Figures 1 to 4) according to the consolidated criteria for reporting 
qualitative research guidelines.19,20 
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Item reduction and formatting of the instruments assessing biologic activity  
     Delphi group members ranked each provided item assessing biologic EoE activity from 0 
(not important) to 5 (very important). The number of items was then reduced by rank order 
from 7 to 5 items, and from 5 to 3 items for histology and blood biomarkers, respectively. 
The number of items (N = 6) for endoscopy did not change. The generated instruments 
were distributed to the Delphi group, and multiple Delphi rounds were conducted to minimize 
interobserver variability, establish clear definitions and to ensure that the final instruments 
reflect the consensus opinion. 
PRO instrument 
     The EEsAI instruments were developed in such a way that PROs are assessed 
separately from items measuring biologic activity.21,22,23,24 The PRO instrument included 
items on symptom severity and behavioral adaptations, which were recalled over 24 hours, 7 
days, and 30 days, to determine the optimal recall period. 
     The PRO instrument contained 5 domains: a general domain to assess socio-
demographic characteristics, two symptom domains to address symptoms dependent and 
independent of food intake, a co-morbidities domain and a medication domain. The PRO 
instrument consisted of 45 items. The domain addressing symptoms while eating or drinking 
includes items on duration, frequency and severity of dysphagia, time required for meal 
intake, dysphagia upon consuming liquids, and pain when swallowing. The Visual Dysphagia 
Question (VDQ) addressed the severity of dysphagia when consuming food of 8 distinct 
consistencies. The 8 food consistencies and examples of foods to illustrate those 
consistencies were as follows: 1) solid meat (such as steak, chicken, turkey, lamb), 2) soft 
foods (such as pudding, jelly, apple sauce), 3) dry rice or sticky Asian rice, 4) ground meat 
(hamburger, meatloaf), 5) fresh white untoasted bread or similar foods (such as doughnut, 
muffin, cake), 6) grits, porridge (oatmeal), or rice pudding, 7) raw fibrous foods (such as 
apple, carrot, celery), and 8) French fries. The examples were chosen based on foods that 
are consumed in the United States, Europe, and Canada. The behavioral adaptations 
(avoidance, modification and slow eating [AMS] of various foods) were also assessed in the 
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context of consuming 8 distinct food consistencies. A domain addressing symptoms 
independent of eating or drinking included items on chest pain, heartburn, and acid 
regurgitation. The last two items were reproduced from the MDQ-30 with the permission of 
the copyright owners.12 
     Patients were asked to provide a Patient Global Assessment (PatGA) of EoE severity on 
an 11-point Likert scale, where a score of 0 is defined as ‘no symptoms’ and a score of 10 is 
defined as ‘most severe symptoms’. The PatGA was used as a main outcome parameter for 
every recall period. The PRO instrument was first created in English. Translation of the PRO 
instrument into German and French was performed in accordance with the World Health 
Organization guidelines for translation and adaptation of instruments.25 
Instruments assessing endoscopic, histologic, and laboratory findings 
     The instrument for physicians consisted of 5 domains: a general domain for physician 
and patient characteristics, a gastro-esophageal reflux (GERD) domain, an anti-eosinophil 
treatment domain, a blood biomarker domain, and an endoscopy domain. The instrument 
also incorporated the physician global assessment of EoE severity (PGA) item. The PGA 
took into account patients’ symptoms (based on history taking), endoscopic, histological, and 
biochemical findings. The PGA was assessed on an 11-point Likert scale, where a score of 0 
was defined as ‘inactive EoE’ and a score of 10 was defined as ‘most active EoE’. The 
endoscopy domain of the physician instrument was designed based on the EoE Endoscopic 
Reference Score (EREFS) classification and grading system.26 
     The histopathology instrument contained three domains: a general domain for 
pathologists and two domains assessing EoE-associated histologic features in the distal and 
proximal esophagus. ‘Distal’ was defined as section of the esophagus 5 cm above the 
gastroesophageal junction, while ‘proximal’ was defined as section spanning the top 1/2 of 
the esophagus. 
The detailed overview of the physician and histopathology instruments can be found in 
supplementary Table 9. 
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Study population 
     The study was registered on clinicaltrials.gov (NCT00939263) and was approved by local 
institutional review boards and ethics committees. All authors had access to the study data 
and reviewed and approved the final manuscript. Between April, 2011 and December, 2012 
(evaluation group) and May, 2013, and July, 2014 (validation group), EoE patients were 
recruited in 1 ambulatory care clinic and 7 hospitals in Switzerland and the United States. 
Adult EoE patients (≥ 17 years of age) in need of an esophagogastroduodenoscopy (EGD) 
for initial diagnosis, for confirming a suspected diagnosis, or for monitoring previously-
diagnosed EoE were invited to participate in the study. Patients provided informed consent 
to participate in the study. EoE was diagnosed by investigators at all centers using published 
diagnostic criteria.3 EoE patients with concomitant GERD were also included if they were 
under a continued proton-pump inhibitor therapy at the time of EGD. All patients underwent 
a standardized physical examination by a physician. EGD was performed and at least 8 
biopsies were obtained (4 from the proximal and 4 from the distal esophagus). Endoscopic 
findings were assessed according to the endoscopy atlas created by Hirano et al.26 Levels of 
blood eosinophils were also measured. Patients completed the PRO instrument before the 
EGD. Gastroenterologists completed the instrument for physicians, while pathologists 
completed the histopathology instrument. 
     Histologic evaluation was performed by the local center pathologist. Five-µm sections 
were cut from paraffin blocks and hematoxylin & eosin stained for examination by light 
microscopy. The area of a high power field and percentage of the area covered by tissue 
were noted to allow for calculation of peak eosinophil counts/mm2. To determine the peak 
eosinophil count, at least 5 levels of every esophageal biopsy specimen were surveyed 
under low power, and the eosinophils in the most densely infiltrated area were counted 
under high power examination. 
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Construction of the visual dysphagia question and avoidance, modification and slow 
eating scores 
     The data obtained from the VDQ and AMS items were used to create a composite score. 
A sample calculation of the VDQ and AMS scores is provided in Appendix 2. 
Data handling and statistical analysis 
     Data were double-entered by two researchers into EpiData database (version 3.1, the 
EpiData Association, Odense, Denmark) and imported into Stata (version 13, College 
Station, Texas, USA) for analysis. Descriptive results are presented as frequencies and 
corresponding percentages of the group total or median plus interquartile range (IQR). We 
used multivariable linear regression analysis and analysis of variance (ANOVA) models to 
identify redundant information and to obtain an equation for constructing a PRO score. In 
these analyses, the PatGA was used as the outcome, and responses to specific items in the 
instrument as predictors. These analyses allowed us to quantify the extent to which included 
items explained the variability in PatGA. The variables included in the final models were 
chosen on the basis of their relative contribution to the explanatory power of the models, 
coherence of parameter estimates and expert opinion. We evaluated the fit of the models 
using the coefficient of determination (R2). To validate the EEsAI PRO instrument, a second 
group of adult EoE patients was included, and the EEsAI PRO score was calculated based 
on the regression coefficients. The R2 was calculated to assess the relationship between 
EEsAI PRO score and the PatGA. A Bland-Altman plot was used to evaluate the agreement 
between the calculated EEsAI PRO score and the PatGA. 
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RESULTS 
Patient characteristics 
     153 and 120 adult EoE patients were recruited for evaluation and validation phase, 
respectively. The characteristics of these patients are shown in Table 1. Age at inclusion, 
sex, ethnicity, and education level were comparable between the two groups. When 
compared to the patients in the evaluation group, the patients in the validation group were 
more likely to have EoE symptom onset > 5 years before inclusion into the study (67.2% vs. 
52.9%), to experience self-reported food allergies (50% vs. 30.1%) and to receive EoE-
specific therapies in the last 12 months before inclusion into the study (85.8% vs. 58.8%); 
however, they were less likely to have concomitant GERD (15% vs. 30.7%) and be treated 
with proton-pump inhibitor therapy (32.5% vs. 55.6%). 
Predominant EoE symptoms (evaluation group) 
     Table 2 illustrates the predominant symptoms of patients in the evaluation group, 
reported over the past 24 hours, 7 days and 30 days. When recalled over the last 24 hours, 
7 days, and 30 days, the median PatGA assessed on the 11-point Likert scale (range 0 - 
10) was 1 (IQR 0 – 3), 2 (IQR 1 - 4) and 2 (IQR 1 - 4), respectively. Forty-one (27.5%), 
91 (59.5%), and 126 (82.4%) patients reported trouble swallowing in the past 24 hours, 7 
days and 30 days, respectively. Overall, except for the meal duration, which remained 
relatively constant over the time periods examined, patients were more likely to experience 
dysphagia and pain events with increasing length of the recall period. 
Assessing dysphagia severity and behavioral adaptations when ingesting foods of 
different consistencies 
     The symptoms of patients in the evaluation group were analyzed for a 24-hour, 7-day and 
30-day recall period. The data of the VDQ and AMS recalled over a 7-day recall period are 
shown in supplementary Table 10. Generally, the severity of perceived dysphagia 
increased with increasing food consistency. For instance, 21 (13.7%) patients reported that 
they expected to experience severe difficulties when eating solid meat, and 11 (7.2%) 
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patients reported the same when eating foods included in a ‘Raw foods’ category. In 
contrast, 5 (3.3%) and 6 (3.9%) patients reported that they expected to experience severe 
difficulties when consuming foods of the ‘Soft foods’ and ‘Grits and porridge’ categories, 
respectively. Increased time required to eat a certain food item was the most common 
complaint for EoE patients. For example, 103 (67.3%) patients experienced this 
phenomenon when eating solid meat, followed by 65 (42.5%) when eating ground meat, and 
54 (35.3%) when eating bread. Food avoidance and food modification were less frequently 
reported for ‘soft foods’ and were mostly associated with high consistency foods, such as 
meat, and ‘Raw foods’, such as vegetables. Similar trends were observed, when data for the 
24-hour and 30-day recall periods were analyzed (data not shown). 
Choosing the appropriate symptom recall period: patient input 
     Patients participating in the focus groups (n = 27) were asked to choose the best time 
period to reliably recall their symptoms. The majority of patients indicated that 7 day-period 
is the best recall period (19/27, 70.4%), followed by 14-day (5/27, 18.5%), 30-day (2/27, 
7.4%), and 24- hour (1/27, 3.7%) periods. 
Development of the PRO score 
     We modeled the PatGA recalled over 24-hour, 7-day and 30-day periods by evaluating its 
strength and significance of association with the items of the PRO instrument. The following 
seven items were chosen for inclusion in the PRO instrument based on their contribution to 
the explanatory power of the models, coherence of parameter estimates and expert opinion: 
frequency of trouble swallowing, duration of trouble swallowing, pain when swallowing, VDQ, 
as well as 3 AMS questions. As the answers to VDQ and 3 AMS items were scored to derive 
VDQ and AMS scores, respectively, the resulting 5 variables were used for the purposes of 
analyses presented below. 
     Frequency of trouble swallowing, duration of trouble swallowing, severity of pain when 
swallowing, VDQ and AMS scores positively correlated with the PatGA for three recall 
periods. The data for the 7-day recall period are shown in supplementary Figure 6. We 
used multivariable linear regression analysis and ANOVA models to evaluate the 
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contribution of chosen PRO variables to the PatGA. The results of these analyses are 
depicted in Table 3. In general, the increasing severity of PRO variables mostly showed a 
positive and significant relationship with the PatGA for three recall periods examined. For 
example, for the 7-day recall period, if a patient experienced daily episodes of trouble 
swallowing, the predicted PatGA increased by 2.61, when compared to 1.3 and 2.29 for 
trouble swallowing episodes experienced 1 - 3 and 4 - 6 times/week, respectively. If, in 
addition, the duration of those trouble swallowing episodes was > 5 minutes, the predicted 
PatGA increased by another 0.53. 
     Although the contribution of 5 PRO variables to the PatGA was similar, when the 7-day 
and 30-day recall periods were examined, the contribution of these variables was quite 
different, when the 24-hour recall period was evaluated. For instance, for patients with a 
highest VDQ score quartile (score ranging from 7.6 to 10 – patients experiencing severe 
difficulties eating various foods), the predicted PatGA increased 6.19 for a 24-hour recall 
period, when compared to the increase of only 1.96 and 1.57 for the 7-day and 30-day recall 
periods, respectively. As such, for a 24-hour recall period, the VDQ score contributed ~ 3 - 
4 times more to the predicted PatGA, when compared to the same VDQ score for the 7-day 
and 30-day recall periods. On the other hand, the coefficients for the highest values of the 
AMS score were quite similar with 2.19 for the 24-hour, 2.15 for the 7-day, and 1.91 for the 
30-day periods. 
     The regression model with 5 variables of the EEsAI PRO instrument explained 72% (R2 
= 0.72), 67% and 58% of the variability in PatGA for the 24-hour, 7-day and 30-day recall 
periods, respectively. Since R2 can be made artificially high by including a large number of 
independent variables that have an apparent effect purely by chance, only 5 independent 
variables that had a large effect were included into the model. Since the EEsAI PRO score 
for a 24-hour recall period was strongly influenced by a response to the VDQ, and the 
frequency of the events, such as pain and dysphagia, was also the lowest for the 24-hour 
recall period, we judged the 24-hour recall period to be less reliable for assessing EoE 
severity. Based on these statistical considerations and patient input, we concluded that a 7-
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day recall period represents the best choice for assessing patient-reported EoE severity by 
the means of the EEsAI PRO score. 
Relationship between patient-assessed EoE severity and biologic EoE activity 
    We observed a positive association between endoscopic/histologic alterations and PatGA, 
which is illustrated by means of box plots in Figure 2. We did not find a correlation between 
PatGA and peripheral blood eosinophil counts (r = 0.045, P = 0.67). 
Validation of the score as well as practicability and content validity of the instrument 
     To validate the PRO score obtained during the evaluation phase, we calculated it for 
every EoE patient recruited in the validation group and compared it with the PatGA. The plot 
in Figure 3A shows that the EEsAI PRO score for the 7-day recall period predicted 65% of 
the variability in PatGA, which closely compares with the 67% of variability in PatGA 
explained by the EEsAI PRO score in the evaluation group. The Bland-Altman plot (Figure 
3B) evaluates the agreement between the calculated EEsAI PRO score and the PatGA. A 
mean difference of only 0.13 between PatGA and EEsAI PRO score was observed. The 
upper and lower 95% limits of agreement were 3.04 and -2.79, respectively. Two versions of 
the validated 7-day EEsAI PRO score are shown in Table 4: 1) the original PRO score that 
ranges from 0 to 8.52 and the 2) ‘user-friendly’ EEsAI PRO score that ranges from 0 to 100. 
     To evaluate the practicability and content validity of the validated EEsAI PRO instrument, 
we again contacted the 27 patients that participated in the focus groups. First, we evaluated 
the time patients needed to complete the EEsAI PRO instrument. When completing the 
instrument for the first time, patients required a median of 8 min (IQR 7 - 9 minutes, range 4 
- 10 min). When asked “How difficult was it for you to complete this questionnaire?”, patients 
responded with a median of 1 (IQR 0 - 2, range 0 - 6; 11-point Likert scale where 0 stands 
for ‘no difficulties at all’, 10 stands for ‘very difficult’). To evaluate content validity, patients 
were asked the Likert scale question: “Does this questionnaire measure the complaints you 
have had / you currently have due to EoE?” Patents responded with a median of 8 (IQR 7 - 
9, range 4 - 10; 10 stands for ‘perfectly’, 0 stands for ‘not at all’). 
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DISCUSSION 
     Eosinophilic esophagitis is a young disease, and, so far, no validated PRO instruments 
reliably assessing disease activity have been approved by regulatory authorities in US and 
Europe. 
     In this article, we describe the process of development and validation of the adult EEsAI 
PRO instrument that assesses EoE symptom severity. We developed the EEsAI PRO 
instrument according to FDA guidelines.16 Patient surveys, focus groups, and semi-
structured interviews were used to gain patient input to inform PRO instrument development. 
The resulting PRO instrument was evaluated in the first group of adult EoE patients. As gold-
standard, we used patient assessment of disease severity (PatGA) to develop the EEsAI 
PRO instrument score. Based on statistical considerations and expert input, seven PRO 
items were selected. These items explained 67% of the total variability in the PatGA over a 7 
day recall period. The EEsAI PRO instrument was validated in a second group of patients, 
and these seven items explained 65% of the variability in PatGA. 
     Assessment of dysphagia is a challenge, because this symptom depends not only on the 
severity of the disease, but also on the consistency of the ingested foods. Moreover, patients 
suffering from dysphagia rapidly develop behavioral adaptation strategies. The EEsAI PRO 
instrument assesses dysphagia caused by eating foods of different consistencies (VDQ) and 
takes into account behavioral adaptation strategies. The food consistencies of the VDQ are 
well-defined, and the foods used to illustrate those consistencies are frequently eaten in 
Western countries. As the VDQ includes items on various food groups, the EEsAI PRO 
instrument can be used to assess dysphagia in individuals with, among others, vegetarian 
dietary patterns, food intolerances, and in patients on elimination diets. Based on patient 
input, the EEsAI PRO instrument is a content-valid measure of EoE symptom severity and 
easy to complete. 
     PRO must be assessed in a defined recall period, but its choice depends on the following 
factors: 1) intended use of the instrument (conceptual framework), 2) the ability of the patient 
to remember the required information, 3) the extent to which the patient with a certain illness 
is burdened when completing the instrument, 4) the nature of the disease and the 
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symptoms, and 5) the study design.27 The choice of a short recall period may lead to 
underestimation of symptom severity, when symptoms have a day-to-day fluctuation, or else 
may place undue burden on the patient, if patients are too ill to frequently complete the 
questionnaire. However, a long recall period may over- or underestimate the true health 
status of the patient. Based on patient preferences and statistical considerations presented 
in this study, the 7-day symptom recall period appears to be most suitable for this chronic 
condition. 
     In the recent years, several PRO instruments have been developed to assess EoE 
symptom severity. The Straumann Dysphagia Index does not assess dysphagia caused by 
eating food of different consistencies and does not take into account behavioral adaptations 
to living with dysphagia.13,14 The MDQ-30 Day version assesses dysphagia due to various 
esophageal diseases, but it has not been developed for EoE specifically.11,12 Using the DSQ, 
Dellon et al. recently evaluated dysphagia to solid food in a group of 35 adolescent and adult 
EoE patients.15 However, the term ‘solid food’ was not defined in the manuscript. In our 
study, we noted important differences in dysphagia severity and behavioral adaptations to 
dysphagia when patients consumed ‘solid food’ of different consistencies. For example, 75% 
of patients expected to experience dysphagia due to consumption of solid meat, whereas 
only 17% of patients expected to experience dysphagia when eating grits or porridge. 
Standardizing the assessment of dysphagia by ingestion of a defined test meal is one way of 
avoiding the complexities associated with the definition of ‘solid food’. However, such an 
approach may not be entirely practical and may raise ethical concerns associated with the 
exposure of the patients to the risk of food bolus impactions.28 The VDQ can be thought of 
as a ‘hypothetical test meal’ that potentially avoids the ethical issues associated with the 
ingestion of a defined test meal. In contrast to findings reported by Dellon et al.15, we found 
that patients frequently reported behavioral adaptations to dysphagia, such as food 
modification, food avoidance, and slow eating. For example, 67% of EoE patients reported 
eating solid meat slower than other people eating this type of food. We conclude that the 
EEsAI PRO instrument is the first to assess dysphagia caused by eating foods of distinct 
consistencies and also takes into account behavioral adaptations. 
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    We observed a positive relationship between endoscopic and histologic alterations and 
patient-assessed EoE severity. We suspect that patients are to a lesser extent sensitive to 
mild endoscopic/histologic alterations when compared to moderate/severe ones. This 
relative lack of sensitivity to mild EoE alterations may explain why the positive correlations 
between EoE symptom severity and endoscopic and histologic findings have been 
documented in some,13,14,29 but not other studies11,30 in both adult and pediatric patients. The 
observed inconsistencies in the correlations between PRO and biologic items may also be 
related to the fact that dysphagia and behavioral adaptations in these studies has not been 
assessed in the context of the various food consistencies. Lastly, the assessment of 
endoscopic and histologic alterations in adult EoE has not been standardized in these 
studies. The recent work by Hirano et al. represents an important milestone in standardizing 
the assessment of endoscopic alterations in EoE.26 At present, the presumed 
pathophysiological mechanisms leading to EoE symptoms involve mucosal inflammation that 
is associated with dysmotility and/or mechanical restriction due to subepithelial fibrosis. We 
have yet to assess the relationship between symptom severity as captured by the EEsAI 
PRO instrument and the esophageal compliance that can be measured by the Endolumenal 
Functional Lumen Imaging Probe (EndoFLIP).31,32 For the purposes of clinical trials, it seems 
prudent to include both PRO and biologic endpoints as untreated eosinophil-predominant 
esophageal inflammation is associated with the generation of esophageal strictures that 
ultimately lead to symptoms.31,33 
     Our study has several strengths, but some limitations as well. We present data of the first 
international multicenter study to develop and validate an activity index for adult EoE 
patients. We followed the recommendations of the FDA for PRO instrument development.16 
While the DSQ applies a scoring algorithm that involves giving a discrete arbitrarily-chosen 
value to each item response,15 the scores for individual items of the EEsAI PRO instrument 
are based on the regression coefficients of the linear regression modeling using PatGA (the 
current ‘gold-standard’ for patient-perceived symptom severity) as the outcome. The EEsAI 
PRO instrument is the first EoE-specific instrument designed to assess dysphagia caused by 
eating 8 different food consistencies and behavioral adaptations to living with dysphagia. As 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Schoepfer et al. Adult Eosinophilic Esophagitis Activity Index PRO instrument Page 23 
such, the validated EEsAI PRO instrument can be used to measure EoE symptom severity 
in patients that do not eat certain food categories, such as vegetarians or patients on specific 
elimination diets. The EEsAI PRO instrument is validated, content-valid, and easy to 
complete. 
     As for limitations, the EEsAI PRO instrument was evaluated and validated for adult 
patients only (≥ 17 years of age). The EEsAI PRO instrument is about to be used in an 
upcoming randomized placebo-controlled clinical trials that will provide data on the 
responsiveness. We also evaluated and validated the PRO instrument for a 24-hour recall 
period, in case completion of the PRO instrument on daily basis might be preferred in certain 
studies. These data will be published elsewhere. The development of an electronic PRO 
(hand-held device) will certainly make the instrument even more ‘user-friendly’. 
    In summary, we report on the development and validation of the adult EEsAI PRO 
instrument to assess EoE symptom severity over a 7-day recall period. The EEsAI PRO 
instrument is content-valid and is easy to complete. The development and validation of an 
instrument for standardized assessment of EoE symptom severity is a matter of paramount 
importance for guiding clinical decision making and for defining the outcome parameters for 
clinical trials as well as epidemiologic studies. 
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FIGURE LEGEND 
Figure 1: Conceptual framework for development of EEsAI instruments. The components of 
the flow chart outlined with a dashed line, such as EndoFlip or mucosal biomarkers, were 
not, as of yet, evaluated for the purposes of the EEsAI study. 
Abbreviations: EndoFlip®, Endolumenal Functional Lumen Imaging Probe. 
Figure 2: The relationship between endoscopic / histologic activity and patient-assessed 
EoE severity. The box contains the 25th - 75th percentile of values, the horizontal line in the 
middle of the box represents the median. 
Figure 3: A. The correlation plot between the EEsAI PRO score and the PatGA in the 
validation group. B. The Bland-Altman plot for the agreement between the EEsAI PRO score 
and the PatGA in the validation group. The grey box indicates the 95 % limits of agreement. 
Abbreviation: PatGA, patient global assessment; EEsAI, eosinophilic esophagitis activity 
index; PRO, patient-reported outcome. 
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Table 1: Patient characteristics. 
 Evaluation group Validation group 
Characteristic Frequency % Frequency % 
Number of patients 153 (100.0) 120 (100.0) 
Males 111 (72.5) 73 (60.8) 
Age at inclusion (median, IQR, range) 38 
(29 - 46; 
17 - 71) 40.5 
(31 - 49; 
19 - 80) 
Ethnicity     
White 148 (96.7) 114 (95.0) 
Non-white 5 (3.3) 6 (5.0) 
Education     
Compulsory schooling 2 (1.3) 1 (0.8) 
Vocational training 38 (24.8) 33 (27.5) 
Upper secondary education 67 (43.8) 54 (45.0) 
University education 46 (30.1) 32 (26.7) 
EoE symptoms onset     
1 to 3 months ago 1 (0.7) 0 (0.0) 
4 to 11 months ago 8 (5.2) 2 (1.7) 
1 to 5 years ago 63 (41.2) 38 (31.7) 
more than 5 years ago 81 (52.9) 80 (66.6) 
Allergic diseases / Allergies     
Asthma 53 (34.6) 42 (35.0) 
Rhinoconjunctivitis 92 (60.1) 72 (60.0) 
Eczema 18 (11.8) 34 (28.3) 
Food allergy 46 (30.1) 60 (50.0) 
Gastro-esophageal reflux disease (GERD) 47 (30.7) 18 (15.0) 
Diagnosis established     
Clinically 28 (59.6) 3 (16.7) 
Endoscopically 11 (23.4) 6 (33.3) 
Based on pH-metric studies 1 (2.1) 2 (11.1) 
Clinically and endoscopically 7 (14.9) 5 (27.8) 
Concomitant medications     
Proton-pump inhibitors 85 (55.6) 39 (32.5) 
Histamine antagonists (H2-receptor) 7 (4.6) 1 (0.8) 
Histamine antagonists (H1-receptor) 25 (16.3) 18 (15.0) 
Inhaled corticosteroids for asthma 4 (2.6) 4 (3.3) 
β2-adrenergic agonists for asthma 20 (13.1) 2 (1.7) 
Leukotriene receptor antagonists for asthma 4 (2.6) 1 (0.8) 
EoE-specific treatments in the last 12 months 90 (58.8) 103 (85.8) 
Hypo-allergenic diets 20 (13.1) 19 (15.8) 
Swallowed topical corticosteroids 65 (42.5) 78 (65.0) 
Esophageal dilation 30 (19.6) 26 (21.7) 
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Table 2: Type and frequency of EoE-related symptoms assessed in the EEsAI PRO instrument over 3 recall periods (N = 153). 
 Recall period 
Characteristic 24 hours  7 days  30 days 
Median symptom severity (IQR; range) 1 (0 - 3; 0 - 10)  2 (1 - 4; 0 - 10)  2 (1 - 4; 0 - 10) 
Frequency of trouble swallowing 
  
 
  
 
  
Never 111 (72.5) Never 62 (40.5) Never 27 (17.6) 
1 to 3 times / day 34 (22.2) 1 to 3 times / week 60 (39.2) 1 to 3 times / month 40 (26.1) 
≥ 4 times / day 7 (4.6) 4 to 6 times / week 15 (9.8) 1 to 3 times / week 52 (34.0) 
 -- --  -- -- 4 to 6 times / week 19 (12.4) 
 -- -- Daily 16 (10.5) Daily 15 (9.8) 
Not applicable 1 (0.7)  -- --  -- -- 
Intensity of trouble swallowing 
  
 
  
 
  
Everything was easy to swallow 111 (72.5)  53 (34.6)  26 (17.0) 
Slight retching 22 (14.4)  69 (45.1)  73 (47.7) 
Food stuck for ≤ 5 minutes 7 (4.6)  25 (16.3)  37 (24.2) 
Food stuck for > 5 minutes 3 (2.0)  4 (2.6)  10 (6.5) 
Impacted food had to be removed 6 (3.9)  0 (0.0)  3 (2.0) 
Missing 4 (2.6)  2 (1.3)  4 (2.6) 
Duration of trouble swallowing 
  
 
  
 
  
No troubles swallowing 107 (69.9)  56 (36.6)  26 (17.0) 
< 15 seconds 24 (15.7)  45 (29.4)  49 (32.0) 
16 to 59 seconds 8 (5.2)  29 (19.0)  34 (22.2) 
1 to 5 minutes 3 (2.0)  18 (11.8)  28 (18.3) 
> 5 minutes 10 (6.5)  5 (3.3)  16 (10.5) 
Not applicable 1 (0.7)  -- --  -- -- 
Time required to eat a regular meal 
  
 
  
 
  
< 15 minutes 24 (15.7)  22 (14.4)  20 (13.1) 
16 to 30 minutes 91 (59.5)  88 (57.5)  86 (56.2) 
31 to 45 minutes 30 (19.6)  34 (22.2)  37 (24.2) 
46 to 60 minutes 3 (2.0)  3 (2.0)  3 (2.0) 
> 1 hour or refusal to eat 3 (2.0)  4 (2.6)  5 (3.3) 
Not applicable 2 (1.3)  2 (1.3)  2 (1.3) 
Frequency of pain when swallowing 
  
 
  
 
  
Never 137 (89.5) Never 122 (79.7) Never 106 (69.3) 
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1 to 3 times / day 14 (9.2) 1 to 3 times / week 21 (13.7) 1 to 3 times / month 19 (12.4) 
4 or more times / day 2 (1.3) 4 to 6 times / week 6 (3.9) 1 to 3 times / week 16 (10.5) 
 -- --  -- -- 4 to 6 times / week 9 (5.9) 
 -- -- Daily 3 (2.0) Daily 2 (1.3) 
Missing 0 (0.0) Missing 1 (0.7) Missing 1 (0.7) 
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Table 3: Linear regression coefficients, 95% confidence intervals (CI) and P-values for the models of Patient Global Assessment of the EoE activity 
(PatGA) recalled over the 24 hours, 7-days and 30-day periods. Abbreviations: Coef, coefficient; CI, confidence interval; VDQ, visual dysphagia 
question; AMS, avoidance, modification and slow eating. 
 
Recall period 
 
 
24 hours   
 
7 days  
  
30 days  
Characteristic Coefa 95% CI P  Coefa 95 % CI P  Coefa 95 % CI P 
Frequency of trouble 
swallowing 
  0.01    < 0.0001    0.0001 
Never 
 ref. ref. Never  ref. ref. Never  ref. ref. 
1 - 3 times / day 1.30 (0.50 - 2.09)   -- -- -- 1 - 3 times / month 0.31 (-0.62 - 1.23)  
≥4  times / day 0.86 (-0.91 - 2.63)  
1 - 3 times / 
week 1.30 (0.74 - 1.86)  1 - 3 times / week 1.28 (0.26 - 2.29)  
-- -- -- -- 
4 - 6 times / 
week 2.29 (1.40 - 3.18)  4 - 6 times / week 2.49 (1.26 - 3.73)  
-- -- -- -- Daily 2.61 (1.66 - 3.56)  Daily 2.46 (1.09 - 3.83)  
Duration of trouble 
swallowing 
  0.03    0.41 
 
  0.52 
≤ 5 minutes ref. ref.   ref. ref.   ref. ref.  
> 5 minutes 1.64 (0.16 - 3.13)   0.53 (-0.76 - 1.83)   0.30 (-0.61 - 1.20)  
Pain when 
swallowing 
  0.10    0.0001 
 
  0.0001 
No ref. ref.   ref. ref.   ref. ref.  
Yes 0.78 (-0.16 - 1.73)   1.27 (0.66 - 1.87)   1.17 (0.58 - 1.75)  
VDQ score 
  <0.0001    0.02    0.01 
0 ref. ref.   ref. ref.   ref. ref.  
0.1 - 2.5 0.14 (-0.66 - 0.93)   1.02 (0.22 - 1.81)   0.40 (-0.60 - 1.39)  
2.6 - 5.0 2.00 (1.02 - 2.98)   1.63 (0.69 - 2.56)   1.64 (0.50 - 2.78)  
5.1 - 7.5 3.22 (1.66 - 4.78)   1.81 (0.43 - 3.20)   1.62 (-0.05 - 3.29)  
7.6 - 10.0 6.19 (4.21 - 8.17)   1.96 (0.45 - 3.47)   1.57 (-0.23 - 3.37)  
AMS score 
  0.20    0.01    0.10 
0 ref. ref.   ref. ref.   ref. ref.  
0.1 - 2.5 -0.04 (-0.73 - 0.66)   -0.57 (-1.24 - 0.10)   -0.35 (-1.13 - 0.43)  
2.6 - 5.0 -0.16 (-1.16 - 0.85)   -0.06 (-0.98 - 0.86)   -0.42 (-1.43 - 0.59)  
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5.1 - 7.5 0.20 (-1.34 - 1.73)   0.77 (-0.59 - 2.12)   0.39 (-1.15 - 1.93)  
7.6 - 10.0 2.19 (0.28 - 4.10)   2.15 (0.46 - 3.84)   1.91 (0.01 - 3.81)  
Constantb 0.39 (-0.21 - 0.98) 0.20  0.38 (-0.14 - 0.89) 0.15  0.88 (0.20 - 1.55) 0.01 
R2c 0.72    0.67    0.58  
 
 
a
 The coefficient represents the change in the value of the predicted PatGA for each category change of the independent variable. For example, 
for a 7 day recall period, the predicted PatGA increased by 1.3 if the patient reported having frequency of trouble swallowing of 1 – 3 times a 
week (category ‘never’ was the reference category). Similarly, the predicted PatGA increased by 2.29 and 2.61 points, if instead of not having 
any trouble swallowing (never), the patient reported having frequency of trouble swallowing of 4 - 6 times/week and daily, respectively. In this 
analysis, with frequency of trouble swallowing, duration of trouble swallowing etc. as independent variables and predicted PatGA as the 
dependent variable, the adjusted regression coefficient for duration of trouble swallowing represents the amount of variation in predicted 
PatGA that is due to the effects of duration of trouble swallowing alone, after frequency of trouble swallowing has been taken into account. For 
example, for a 7 day recall period, if the patient experienced daily episodes of trouble swallowing (with predicted PatGA increase of 2.61 
points), his/her predicted PatGA increased by another 0.53 points, if the duration of those trouble swallowing episodes was > 5 minutes. 
b
 The constant represents the value of the predicted PatGA when all 5 values of independent variables are zero. 
c
 The coefficient of determination, R2, is a measure of the extent to which the regression model describes the observed data. The closer the R2 
is to 1, the more precise the regression model is. Since R2 can be made artificially high by including a large number of independent variables 
that have an apparent effect purely by chance, only independent variables that have a large effect have been included in the model. This was 
also done to ensure that the statistical model is clinically meaningful and can be easily interpreted. 
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Table 4: EEsAI PRO score for the 7-day recall period. The score based on regression 
coefficients that ranges from 0 to 8.52 is shown in column 1. For clinical ease of use, a total 
of the score based on the regression coefficients was set to 100 and values for each 
category adjusted accordingly. This score is shown in column 2. Abbreviations: VDQ, 
visual dysphagia question; AMS, avoidance, modification, and slow eating score. 
Item   Score (based 
on regression 
coefficients) 
Score (total 
set  
to 100) 
Frequency of trouble swallowing Never 
1-3 times/week 
4-6 times/week 
Daily  
0 
1.30 
2.29 
2.61 
0 
15 
27 
31 
Duration of trouble swallowing ≤5 minutes 
>5 minutes 
0 
0.53 
0 
6 
Pain when swallowing No 
Yes 
0 
1.27 
0 
15 
VDQ score  0 
0.1-2.5 
2.6-5.0 
5.1-7.5 
7.6-10.0 
0 
1.02 
1.63 
1.81 
1.96 
0 
12 
19 
21 
23 
AMS score  0 
0.1-2.5 
2.6-5.0 
5.1-7.5 
7.6-10.0 
0 
0 
0 
0.77 
2.15 
0 
0 
0 
9 
25 
Total  
 8.52 100 
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APPENDIX 1 
 
Development and Validation of a Symptom Activity Index for Adults with Eosinophilic 
Esophagitis: Qualitative Methods 
This section describes in detail the qualitative methods used to develop and validate the EEsAI 
PRO instrument. Findings are reported according to the consolidated criteria for reporting 
qualitative research (COREQ).19 
PATIENTS AND METHODS 
     The EEsAI study is registered under clinicaltrials.gov (NCT00939263) and approved by the 
institutional review boards and ethics committees of the participating centers. The qualitative 
work reported in this paper was conducted in Switzerland (Cantons of Bern and Solothurn) and 
at the Northwestern University, Chicago, USA. All participants provided written informed 
consent. 
Research Team and Reflexivity 
     The research team was composed of experts in the field of EoE (AMS is a practicing male 
gastroenterologist, MD; AS is a practicing male gastroenterologist, MD; IH is a practicing male 
gastroenterologist, MD; NG is a practicing female gastroenterologist, MD), general internal 
medicine (Emily Kern, MD), mucosal immunology (ES is a female immunologist, PhD), 
veterinary medicine (EM is a female veterinarian, PhD), epidemiology (RP is a male 
epidemiologist; CK is a female pediatric pulmonologist and epidemiologist, MD, MSc; MZ is a 
male epidemiologist, PhD, PRO design (KK is a male PRO specialist, PhD; BS is a female PRO 
specialist, PhD), statistics (MC is a male statistician, PhD), and psychology (TT is a female 
psychologist, PhD; KM is a female psychologist, MSc) with specific expertise in qualitative 
research. NH is a female research assistant, BSc. 
     The interviewer TT, KM as well as BS were trained in qualitative methodology as part of 
university studies and research activities; interviewer EK as well as facilitators AMS and AS 
received training in qualitative research methodology for the purposes of this study. Those 
performing content analysis (ES, AMS, NH, and EM) received the training in qualitative research 
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methodology for the purposes of this study. TT, CK, MZ, and ES have conducted research on 
various aspects of EoE for > 5 years, RP, MC, EM, and NH conducted EoE research for at least 
one year. KK, KM, and BS received a background training on various aspects of EoE related to 
this study specifically for the purposes of this study. AS, AMS, IH, and NG are experts and 
published extensively on EoE. 
     Patients participating in the survey had an established relationship with treating physicians 
(AS, IH, NG). Patients participating in the survey were informed about the purpose and research 
interest of the research team through a letter that described the purpose of the study. Patients 
that participated in the focus groups had an established relationship with the treating physician 
(AS), but no previous relationship with AMS and KM. Prior to the focus groups, patients were 
provided the information about the study and the research interests of AMS and AS. Patients 
participating in the face-to-face semistructured interviews had an established relationship with 
the treating physicians (IH, NG), but no previous relationship with EK. 
Study design 
Theoretical Framework 
    Given the fact that there is no single ‘gold-standard’ to gain patient input for PRO 
development, we chose a mixed methods approach by gathering patient’s input by means of 
surveys, focus-groups, and individual interviews (Supplementary Figure 1). The content 
analysis was performed using a deductive category application approach described by 
Mayring.20,34 This method allows separation of the data from the text and systematic reduction of 
the information.20,34,35 We followed the COREQ guidelines when reporting the results of this 
study.19 
Participant selection and setting 
     Diagnosis of EoE was established according to published criteria.3 Patients with EoE and 
concomitant gastro-esophageal reflux disease that was under treatment with at least a standard-
dose of proton pump inhibitors were included into the study. 
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     Patients participating in the survey: A total of 110 EoE patients in Switzerland (AS) and 
287 EoE patients in Northwestern Medical Center, Chicago, USA (IH and NG) were addressed 
to participate in the study. EoE patients were sent questionnaires by mail. Patients completed 
these at a place of their choice and returned the completed questionnaires by mail. 
     Patients participating in the focus groups: Thirty-two EoE patients were approached 
during a routine clinical visit in EoE clinic, Olten County, Switzerland, and invited by AS to 
participate in the focus groups. Five patients declined the invitation. Twenty-seven EoE patients 
were interviewed in 3 focus groups (n = 9 for each focus group). Interviews were conducted at 
the EoE clinic in Olten, Switzerland. Except for the interviewer (KM) and two facilitators (AMS, 
AS), no one else was present at the time of the focus groups. 
      Patients participating in the individual patient interviews: A total of 30 patients were 
approached during a routine clinical visit at a university based gastroenterology practice and 
invited by IH and NG to participate in the face-to-face patient interviews. Six patients declined 
participation. Interviews were conducted in Northwestern Medical Center, Chicago, USA. 
Data collection 
     Eosinophilic esophagitis symptom questionnaire used in the survey: The EoE symptom 
questionnaire consists of seven close-ended questions designed to address participants’ age, 
sex, country of citizenship, education and current occupation and two open-ended questions 
assessing EoE-related symptoms and their severity (supplementary Table 1). For each open-
ended question, we provided an example of the way an answer to this question might be given 
and a space of 4 lines for description of a single symptom or complaint. We also provided an 11-
point Likert scale for patients to rank the severity of a given symptom (supplementary Figure 
2). For each open-ended question, a space for description of up to 6 concerns or symptoms was 
provided. Patients were asked to write any other additional symptoms they might have 
experienced on a separate sheet of paper, if they were to run out of space. The questionnaire 
was developed in German (Olten County is located in the German-speaking part of Switzerland). 
The EoE symptom questionnaire in German was translated into US English as described by 
Acquadro et al.36 During the pilot study, 15 study participants were asked to complete the 
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questionnaires. Following the completion of the questionnaires, patients were interviewed to 
provide feedback. Patients judged the questionnaires to be appropriate to capture EoE-related 
symptoms and easy to complete. 
     Focus groups: Subjects participated in the focus group guided by an experienced 
psychologist (KM) to learn about the patient’s symptoms and other experiences with EoE. AMS 
and AS were present as facilitators. A priori themes, such as symptoms during food intake or 
symptoms when not eating or drinking, behavioral adaptations to living with dysphagia, 
impairment in social and professional activities, experience with treatments and endoscopies, as 
well as other concerns were developed based on the existing literature, the experience of the 
research team or were adopted and/or reproduced directly from a study by Tufts et al. with 
permission of the senior investigator (IH).1-4,8,37 The open-ended questions were constructed in 
German language, a translation of these questions into English is provided in supplementary 
Table 2. Three repeat focus groups were carried out in Swiss dialect of German language. The 
focus groups lasted between 1.5 and 2 hours. All sessions were audio-recorded, translated and 
transcribed in German, since Swiss dialect of German is not a written language. The research 
team reviewed transcriptions of the focus groups. The transcripts were analyzed by the lead 
investigator (AS) and the research team (ES, EM, NH). Field notes were taken by AS. 
Transcripts were not returned to participants for further comments. Since no new theme has 
arisen during the last two focus groups, no additional focus group interviews were carried out. 
     The patients participating in the focus group interviews for item generation were contacted at 
later time points to provide feedback about the best recall period to assess EoE symptoms, to 
assess the content validity and the practicability of the EEsAI PRO instrument. 
     Individual patient interviews: Twenty-four EoE patients, underwent individual face-to-face 
semistructured interviews guided by a trained physician (EK) to inquire about the symptoms and 
other experiences with EoE. No facilitator was present during the individual interviews. 
Interviews were conducted in English. The set of questions has been previously published by 
Taft et al.37 An individual patient interview lasted between 50 to 60 minutes. Following the 
interview, patients underwent a debriefing with the interviewer, to better understand various 
reasons behind patients’ responses. Field notes were taken by the interviewer after the 
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individual patient sessions. All interviews and debriefing sessions were audio-recorded and 
transcribed. The transcripts were analyzed by the local investigators (EK, TT, IH, NG) and the 
research team in Switzerland (ES, NH, AMS). 
Analysis and findings 
     Development and description of the code book: Based on the review of the existing 
literature and the proposals of the multidisciplinary research team, the conceptual model was 
developed (supplementary Figure 3), and the preliminary version of the codebook was 
derived.1-4 The input from patients and the expert discussions were designed to elicit concepts 
related to patient experiences with EoE symptoms to inform an EoE symptom severity 
instrument development. 
     Data analysis: We conducted a computer-assisted content analysis according to Mayring 
using ATLAS.ti software, version 5.0 (ATLAS.ti, GmbH, Berlin, Germany).20,34 We established 
definitions and coding rules for each main code category and its sub code categories prior to the 
coding (see development and description of the code book). The unit of analysis was defined as 
all words and sentences related to the description of a single symptom or a problem (written 
within the four lines provided per discomfort). The complete transcripts of surveys, focus groups, 
and individual patient interviews were read by 2 coders (AMS and ES). As questionnaires were 
completed in two languages, three coders with proficiency in English and German analyzed the 
material. Categories were discussed among coders until mutual agreement was reached. One 
researcher (ES) analyzed all the material using these code categories, and categories were 
revised or expanded, if necessary, in order to saturate the content of the material provided. As a 
formative check of reliability, we clarified definitions, as well as new and obsolete codes, until 
consensus about saturation was reached. The final codes were applied to all the text 
(Supplementary Table 3). As a part of summative check of reliability, the final matching of main 
code and sub code categories, as well as their validity, were discussed by a research team, and 
agreement was reached, when opinions differed. Given the fact that Taft et al. already described 
the impact that EoE has on several psychosocial domains, we specifically analyzed the 
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transcripts of semistructured interviews for description of the physical complaints and those 
psychosocial domains related to adaptations to living with dysphagia.37 
     The socio-demographic data were entered in a database created in EpiData, version 3.1 
(EpiData Association, Odense, Denmark). Descriptive analyses were performed using Stata, 
version 11.2 (Stata Corporation, Austin, Texas).
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RESULTS 
Response rate, characteristics of the study population 
    Supplementary Table 4 provides an overview of the socio-demographic characteristics of the 
study sample overall which consists of patients having participated in the surveys, in the focus 
group interviews, and in the individual patient interviews. A total of 397 consecutive EoE patients 
were addressed by treating physicians to participate in the survey in Switzerland and the United 
States, respectively. Response rates were 19.2 % (55/287 patients) in the United States and 
72.7 % (80/110 patients) in Switzerland. The results are based on the responses provided by 
135 patients. Of a total of 617 statements, 467 (75.7 %) described symptoms while eating (a 
statement represents one answer written within the four lines provided per discomfort). Fifty-
three patients (39.3%) reported only discomfort related to eating or drinking. For focus groups, 
32 Swiss patients were invited with 5 patients declining participation (response rate of 84 %). For 
semistructured face-to-face interviews, 30 US patients were approached with 6 patients 
declining participation (response rate of 80%). All patients had confirmed EoE diagnosis at the 
time of participation in the study.  
Qualitative Analysis 
Major themes 
     Three key themes and two subthemes emerged: the definitions of dysphagia and dysphagia 
characteristics, dysphagia caused by different foods, pills and beverages, behavioral adaptations 
to living with dysphagia (two subthemes: strategies aimed to avoid impaction and strategies 
dealing with impaction, once it occurred). The key domains and their relationships are illustrated 
in supplementary Figure 4. 
Definition of dysphagia and dysphagia characteristics 
     In supplementary Table 5, sample quotation of the description of dysphagia events and the 
specific characteristics of these events provided by the patients are shown. Participants 
described dysphagia in terms of difficulty swallowing, solids/liquids passing slowly or not 
smoothly, feeling of tightness, and most commonly as impaction events, characterized by food 
being stuck or lodged in the esophagus or else by choking on food. Dysphagia events were 
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described by patients to be occurring in the throat and chest or esophagus. We were able to 
identify various characteristics and attributes of dysphagia, such as duration, frequency and 
severity of dysphagia events. The duration of dysphagia events ranges from a few seconds, to 
minutes, to many hours, especially if impacted food had to be removed by endoscopy. The 
frequency of dysphagia ranges from “infrequent” events, to those occurring a few times a week, 
and, finally, to those occurring “every day and every time one eats”. Patients often mentioned 
that various disease treatments diminished the frequency or the severity of the dysphagia 
events. 
Dysphagia caused by eating different foods, pills and drinking beverages 
     Patients frequently described dysphagia events caused by eating certain foods, drinking 
beverages or swallowing pills. In supplementary Table 6, the sample quotation of the 
describing dysphagia events caused by eating foods, swallowing pills and drinking beverages is 
shown. Of all the foods causing dysphagia, meat was most frequently mentioned, followed by 
bread and rice. However, other foods, such as uncooked fruits and vegetables, ground meat, 
French fries and pasta also caused trouble swallowing in patients with EoE. Patients also 
described dysphagia caused by swallowing large pills. In addition, drinking liquids also caused 
dysphagia events. Patients were also likely to specify that alcoholic beverages were causing 
these events. Lastly, patients occasionally mentioned foods that do not cause dysphagia and are 
easy to swallow. 
     Patients also used various adjectives to describe foods that cause dysphagia, of these “solid” 
and “dense” were most frequent, but “heavy”, “tough” or “thick” were also used. Mostly these 
adjectives were used in the context of dysphagia caused by eating meat, although other foods 
were also mentioned. Similarly, adjectives “fibrous” and “course” were also frequently used to 
describe foods causing dysphagia; most frequently these adjectives were used to describe 
uncooked vegetables, but these were also occasionally used in the context of eating meat. 
Lastly, the adjective “dry” was frequently used to describe dry foods, such as popcorn and chips, 
that also caused dysphagia, but this adjective was also frequently used in the context of 
dysphagia events caused by eating meat. 
Behavioral adaptations to living with dysphagia 
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     Over the years, patients have developed various strategies to avoid impaction events or to 
deal with them, especially to avoid going for emergency treatment. Examples of these strategies 
are shown in supplementary Table 7. The following strategies for avoiding impaction events 
were used by EoE patients: food avoidance, food processing, eating carefully / slowly and 
drinking liquids to wash down the food. Patients mostly avoided eating meat, although rice, 
bread and vegetables were also described as foods to be avoided. Patients also processed their 
foods to avoid food impaction events, of which the most common strategy was to cut meat in 
small pieces before consuming it. Other strategies involved peeling apples before eating them or 
eating foods with sauces to facilitate swallowing. Patients also described that eating slowly, 
carefully, taking smaller bites out of their foods and chewing carefully helped them to avoid 
impaction episodes. Patients also mentioned that eating quickly would lead to dysphagia 
episodes; we interpreted these statements as indication of eating slowly as strategy to avoid 
dysphagia. Lastly, many patients mentioned that they nearly always had something to drink 
during mealtimes. The strategies of dealing with impaction events were also frequently 
mentioned by the patients. For the purposes of coding, these strategies had to be used in the 
context of impaction events, described as foods “sticking” or “lodging itself” in the chest, 
esophagus or throat. These strategies included trying to induce “choking”, “coughing” or vomiting 
of impacted food. Waiting for impaction to resolve itself was also a very common strategy. 
Patients also used liquids to wash down impacted food. This strategy was different from the 
strategy of avoiding impaction by drinking liquids, which was defined as something occurring 
regularly when eating. Liquids were frequently described as either helping to resolve impaction 
events or not. Patients also used other strategies, like relaxing, walking and doing physical 
activity, such as jumping to trying to resolve the impaction event. 
Other themes 
     Other themes identified in the process of our analysis included swallowing-associated pain, 
non-swallowing associated pain, allergic reactions related to food intake, gastro-esophageal 
reflux disease-like symptoms and treatments. In supplementary Table 8, the sample quotation 
for these themes is shown. 
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     Patients mentioned that swallowing and particularly episodes of impaction were associated 
with pain mostly occurring in the chest / esophagus, although sometimes also in belly / stomach. 
Characteristics of these swallowing-associated pain episodes, such as description of pain, 
frequency, duration or severity were also described. Similarly, non-swallowing associated pain 
(and its characteristics), defined for the purposes of coding as pain occurring outside the time of 
eating or drinking and not occurring at the time of impaction, was also mentioned by the patients. 
Patients also described allergic reactions related to food. For the purposes of coding, this was 
defined as itching, swelling or irritation of the mouth. Patients described this occurring when 
consuming fruits, dairy and wheat products, such as bread and beer. Lastly, patients mentioned 
experiencing gastro-esophageal reflux disease-like symptoms, including heartburn and acid 
regurgitation, often described as “reflux” or “acid reflux”. 
    As treatments, patients mentioned endoscopic desimpactions, dilation, as well as treatments 
with anti-acid / gastro-esophageal reflux medications and swallowed topical corticosteroids. 
Mostly patients mentioned treatment with medications and dilation in the context of feeling better 
after these treatments, although side-effects of corticosteroid intake, such as fungal infection, 
were also described. In case of food impactions requiring endoscopic removal, these were 
mentioned in the context of being unable to swallow one’s saliva and worrying, fearing or 
panicking during these extreme episodes. Other treatments were mentioned in connection with 
other allergic disorders, such as asthma. 
     Although assessing the themes related to psychosocial function lying outside of disease-
modifying behavior was outside the scope of our study, patients mentioned that they were 
concerned, often panicking, when experiencing episodes of food impaction. Patients also 
mentioned that they were concerned about meal times both at home and when eating out, 
especially in the presence of company. 
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Supplementary Table 1: Open-ended questions used in the patient survey to gain input on 
eosinophilic esophagitis-related symptoms. 
Question Wording of the question 
Open-ended question 
1: Discomfort while 
eating 
Please describe any discomfort that you have experienced while eating or 
drinking that is due to eosinophilic esophagitis. 
Open-ended question 
2: Discomfort not 
related to eating or 
drinking 
Please describe any discomfort related to eosinophilic esophagitis that 
occurs at times when you are not eating or drinking. In other words, 
symptoms that occur between meals. 
Defining the question Please try to explain your symptoms as precisely and clearly as possible.  
Giving examples for the 
definition 
For example: If you have pain, where exactly is the pain? In your throat, 
stomach, chest, etc.? How long does the pain last? How intense is the 
pain? How often do you have pain, etc.? 
Explaining the 
procedure 
If you have more than 6 symptoms, please describe them in detail on a 
separate sheet of paper. 
Explaining the severity 
scoring for each 
symptom 
A score of 0 (not annoying) indicates that you don’t have the symptom, 
while a score of 10 (very annoying) indicates that the symptom is very 
strong, almost unbearable. 
Giving an example how 
it would look like when 
being filled 
Supplementary Figure 2 (example for question 1) 
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Supplementary Table 2: Semi-structured questions for focus groups. Abbreviation: EoE, 
eosinophilic esophagitis. 
Question 1: How would you describe to someone else what EoE is? a 
Question 2: How old were you when you were diagnosed with EoE? 
Question 3: What sources did you use to learn more about EoE? a 
Question 4: 
What symptoms did you have because of your EoE? Please describe first the 
symptoms that occurred during meal times and then the symptoms that occurred 
independent of meal times. 
Question 5: Have you avoided or do you avoid certain foods? 
Question 6: Have you modified/changed certain foods? 
Question 7: 
Have you eaten longer than other people? If yes, how long do you need to eat a 
meal? 
Question 8: What impact EoE has on your professional life? 
Question 9: What impact EoE has on your social life? 
Question 10: What impact EoE has on your activities, including sport, in your spare time? 
Question 11: What was your experience with endoscopies and foods that got stuck? a 
Question 12: Since being diagnosed with EoE, have you told anyone about it? a 
Question 13: Did you undergo allergy testing? a 
Question 14: 
What are your concerns regarding the long-lasting evolution of your EoE? Do you 
worry about cancer? Do you worry about new episodes of foods getting stuck? a 
Question 15: 
What have your experiences been with swallowed steroids? Diets? Stretching of the 
esophagus? a 
Question 16: What is the most difficult thing about having EoE? a 
Question 17: 
Compared to any other current medical problems you once had, where does EoE 
stand?a 
 
a These questions were adopted or reproduced directly from a study by Tufts et al.47  with permission of 
the senior investigator. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Schoepfer AM, et al. EEsAI PRO Instrument. Supplementary material. Page 13 of 28 
 
Supplementary Table 3: Coding tree. 
Main code Sub codes 
 
Dysphagia 
• Definition, impaction 
• Definition, tightness 
• Definition, difficulty swallowing 
• Definition, solids / liquids passing slowly or not smoothly 
• Location, throat 
• Location, chest/esophagus 
• Duration 
• Frequency 
• Severity 
• Unable to swallow/build-up of saliva 
 
Dysphagia caused by different foods, pills and beverages 
• Description, compact / solid 
• Description, dry 
• Description, fibrous 
• Foods specified, meat 
• Foods specified, bread 
• Foods specified, pill 
• Foods specified, raw fibrous 
• Foods specified, rice 
• Foods specified, French fries 
• Foods specified, pasta 
• Other / unspecified 
• Beverages specified, alcohol-containing 
• Beverages, other / unspecified 
 
Foods not causing dysphagia 
 
Strategies avoiding impaction 
• Food avoidance 
• Food processing  
• Eat slowly / Trigger – hasty eating 
• Washing food down – helps 
• Washing food down – does not help 
 
Strategy dealing with dysphagia event 
• Choke / cough impacted food out 
• Vomit impacted food 
• Waiting until impaction resolves itself 
• Washing food down – helps 
• Washing food down – does not help 
• Other strategies mention / not specified 
 
Swallowing-associated pain 
• Location, throat 
• Location, chest/esophagus 
• Location, belly/stomach 
• Description, burning 
• Duration 
• Frequency 
• Severity 
• Circumstances, with food impaction 
• Circumstances, with food but no impaction 
• Circumstances, with beverages 
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Non-swallowing-associated pain 
• Circumstances 
• Description 
• Location, chest 
• Location, belly/stomach 
• Location, throat 
• Duration 
• Frequency 
• Severity 
 
Allergic manifestations 
• Allergies related to food, location, throat 
• Allergies related to food, location, esophagus 
• Allergies related to food, duration of event 
• Foods causing allergies 
• Afflictions mentioned, allergic reactions not for food 
• Symptom, itching/scratching/irritation 
• Symptom, throat swelling 
• Symptom, tightness 
 
Treatments 
• Anti-acid/GERD medications 
• Dilation 
• Endoscopic desimpaction 
• Swallowed topical corticosteroids 
• Diet 
• Not specified 
• Treatments for concomitant allergic diseases 
 
Gastro-esophageal reflux disease-like symptoms 
• Definition, heartburn 
• Definition, acid regurgitation/reflux 
• Definition, gastro-esophageal reflux disease 
• Location, chest 
• Circumstances 
• Duration 
• Frequency 
• Severity 
• Pain 
 
Other concerns 
• Symptoms, sweating 
• Symptom, vomiting 
• Symptom, problems breathing / choking 
• Symptom, pressure on the chest 
• Symptom, nausea 
• Symptom, foreign body sensation 
• Symptom, clearing ones throat 
• Symptom, belching/gas/burping 
• Overall duration of disease / symptoms 
 
Psychological concerns 
• Psychological factors, worry about potential impaction 
• Psychological factors, feelings during impaction 
• Psychological factors, reduced enjoyment of mealtimes 
• Psychological factors, other 
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Supplementary Table 4: Characteristics of the study population. 
Source of input Patient survey Focus 
Groups 
Interviews 
Provenience Switzerland USA Switzerland USA 
Patient numbers N % N % N % N % 
Responders 80 100 55 100 27 100 24 100 
Sex 
    
    
Men 62 77.5 31 56.4 19 70.4 17 70.8 
Women 18 22.5 24 43.6 8 29.6 7 29.2 
Age at time of questionnaire 
completion (years) 43.4 ± 14.4 43.2 ± 10.6 45.8 ± 14.5 39.1 ± 11.4 
Education 1 
    
Compulsory schooling 2 1 1.2 0 0 0 0 0 0 
Vocational training 3 35 43.7 5 9.1 12 44.4 0 0 
Upper second. education 4 31 38.8 23 41.8 12 44.4 3 12.5 
University education 5 13 16.3 27 49.1 3 11.2 21 87.5 
Migration 
    
No migration background 74 92.5 54 98.2 27 100 24 100 
Migration background 6 7.5 1 1.8 0 0 0 0 
 
Abbreviation: N = Number of individuals 
1
 Education: Systems are different in Switzerland and the USA. We compared the different levels 
according the International Standard Classification of Education (ISCED). 
2
 Basic education: in both countries 9 years (ISCED codes 1 - 2). 
3
 Secondary education: high school; vocational training; apprenticeship; grammar school (leads in 
Switzerland to a “Maturity degree” and is the regular pathway to university education); teachers’ 
college (was in Switzerland the regular pathway to be a primary school teacher until very recently) 
(ISCED codes 3 - 4). 
4
 First stage tertiary education: Switzerland: bachelor’s degree, or additional schooling, that leads to 
higher degrees/managerial jobs in specific professions, e.g. in economics, social work, engineer, 
journalist, etc. USA: some college but no degree, associate’s degree, bachelor’s degree (ISCED 
codes Switzerland: 5.1 - 5.6, 5.8; USA: 5.1 - 5.3). 
5
 University education: University degree, e.g. master’s degree, doctorate degree, medicine/MD, 
law/JD/LLB (ISCED codes Switzerland: 5.7, 5.9 - 5.14, 6; USA: 5.4 - 5.8, 6). 
6
 Migration background defined as: participant moved to Switzerland/USA after birth, or was not a 
Swiss/US citizen at the time of the questionnaire completion, or became Swiss/US citizen after 
birth. 
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Supplementary Table 5: Dysphagia and its characteristics. 
Definition of dysphagia    
Impaction Tightness Difficulty swallowing Solids/liquids passing slowly or not 
smoothly 
• There are times when I will eat sandwiches and 
bites will get stuck for about 30 seconds. 
• When I eat red meat, I will occasionally have a 
feeling of tightness or impaction. 
• Sometimes eating chicken or other meats is tough 
to swallow. 
• When I eat chicken I feel it either slowly go down 
or get stuck in my throat. 
• When taking medication sometimes the pills get 
temporarily stuck in my throat. 
• When I eat red meat, I feel a tightness in my throat 
- often times I need to walk around and swallow 
continuously to allow swallowing the food. 
• When eating sometimes just have a hard time 
swallowing. Throat does not clog but just closes 
enough to make eating and drinking difficult. 
• Sometimes meat or very heavy foods do not go 
down smoothly. 
• Sometimes when I eat bread or meat it will 
become lodged in my esophagus and takes a long 
time (> 5 min) to completely be swallowed (move 
down into stomach). 
• Prior to treatment I would experience a painful and 
complete constriction of my throat, a complete 
choking sensation. Nothing would relieve it, only a 
few minutes for it to clean. 
• Symptoms are better or less obvious now that I 
take Nexium a day. Don’t seem to choke or have 
as much difficulty while swallowing after eating. 
• Earlier, when I was experiencing symptoms, I had 
trouble swallowing. Things, especially sandwiches, 
would get “stuck” or slow down before getting to 
my stomach. 
• When I eat rice, I have difficulty swallowing or 
sometimes it feels like it gets stuck in my throat. 
• Sometimes when I eat, I feel a tightness in my 
upper chest, back of throat. I drink a lot of water 
virtually every time. 
• I have trouble swallowing - very, very painful and 
many choking experiences. 
• When I eat at every meal, it doesn’t matter what 
type of food, I notice that the food goes down the 
esophagus somewhat slowly.  
• Most of my symptoms are related to choking on 
foods - very painful. 
 • If I am very stressed or upset, I find some difficulty 
in swallowing liquids. 
 
Dysphagia characteristics    
Dysphagia duration Dysphagia frequency Dysphagia severity Dysphagia Location 
• When I eat food (various things) sometimes it gets 
stuck in my throat for a few seconds, then goes 
down. 
• Tightness in my throat when eating hamburgers, 
sandwiches too quickly. Infrequent symptoms. 
• Symptoms are better or less obvious now that I 
take a Nexium a day. Don’t seem to choke or have 
as much difficulty while swallowing after eating. 
• Esophagus: Sometimes when I eat bread or meat 
it will become lodged in my esophagus and takes a 
long time (more than 5 min) to completely be 
swallowed (move down into stomach). 
• When I eat bread (or bagels) I feel a tightness in 
my throat / upper chest. It usually goes away after 
20-30 seconds. I stop eating and focus on relaxing 
and may drink water to make it go away. 
• Prior to treatment I would experience a painful and 
complete constriction of my throat, a complete 
choking sensation. Nothing would relieve it, only a 
few minutes for it to clean. This would happen 
relatively often 1 or two times per week after eating 
“dense” foods. 
• Occasionally when I eat, I feel a tightness that is 
severe. I hope when I drink something that it will 
go away. 
• Throat /Chest: Pork (especially pork chops) always 
cause tightness in throat / chest. It lasts 30+ 
seconds but my throat/chest will feel sore for a 
while. 
• I have to take smaller bites, wait until it [food] goes 
down then I can eat again. It takes about 5 
seconds between bites. 
• Most frequently when I have a problem the food 
will get stuck for 10-20 seconds. Sometimes I try to 
get it down by swallowing water which may or may 
not work. There is a slight discomfort and tightness 
in my esophagus but I can always tell that it will go 
down and eventually it does go down by itself. I 
can usually start eating again after that. If I have a 
second incident during the same meal, I will stop 
eating. That occurs maybe 50% of the time. 
• Most frequently when I have a problem the food 
will get stuck for 10-20 sec. Sometimes I try to get 
it down by swallowing water which may or may not 
work. There is a slight discomfort and tightness in 
my esophagus but I can always tell that it will go 
down and eventually it does go down by itself. I 
can usually start eating again after.  If I have a 
second incident during the same meal, I will stop 
eating. I rate this symptom as a 4 [on a scale from 
0 to 10] unless it reoccurs during the same meal, 
then it is a 6. 
• Throat: Pieces of meat have severely gotten stuck 
in my throat producing the feeling of choking - but 
obviously not in the airways. Happens several 
times per year. 
• When eating meat, I would have a problem if I 
swallowed too big of a bite. I would get stuck in my 
throat and sometimes be stuck for hours. 80% of 
the time it would only be stuck for a few minutes. 
• My most recent symptom is various types of solid 
foods getting stuck in my throat. It will not go down 
with dry swallowing, but will go down with one to 
two drinks of liquid. It happens once or twice a 
week. 
 • Throat: Dry chicken (white meat) causes tightness 
in my throat / chest that lasts 10-20 seconds. 
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Supplementary Table 6: Dysphagia caused by different foods, pills and beverages. 
Meat Pills Bread Other foods / unspecified 
• Periodically meat will remain in my esophagus for 
several minutes and coughing or throwing up 
seem to be the only solution. 
• Difficulty swallowing pills due to a history of 
dysphagia with larger pills. More a mental 
annoyance that I get concerned about swallowing 
pills. I take a “gummy” chewable multivitamin 
instead of a pill. 
• Sometimes when I eat bread or meat it will 
become lodged in my esophagus and takes a long 
time (more than 5 minutes) to completely be 
swallowed (move down into stomach). 
• When I eat items like crackers, peanuts, popcorn 
etc. - the material that’s finely chewed gets stuck in 
my throat.  This material is not easily washed down 
with water. 
• Sometimes eating chicken or other meats is tough 
to swallow. 
• When I take pills, they must be very small or it will 
get stuck in my throat. Nothing like water helps, so 
I must try to throw up the pill. 
• When I eat meat or breads, they are hard to pass 
down my esophagus.  My passage becomes 
restricted and I am forced to wait until the food 
passes (30 min - 3 hours) or try to physically throw 
up the blockage. 
• Earlier, when I was experiencing symptoms, I had 
trouble swallowing. Things, especially sandwiches, 
would get “stuck” or slow down before getting to 
my stomach. They would clear with liquids.  
• Sometimes when I eat meat, I feel a scratch in my 
throat or a light tightness that remains until I wash 
it down with a fluid. 
• Cannot swallow pills – that is how I first came 
across my problem, got stuff in my esophagus and 
had severe choking for several hours.. 
• When I eat food (various things) sometimes it gets 
stuck in my throat for a few seconds and then goes 
down (examples of foods may be bread). 
• When I eat potato chips, sometimes chip 
fragments hang up in my throat. Generally, they 
pass naturally. 
• When I eat meat too much too quickly I have to 
wait to let the food pass. 
   
Pasta Raw fibrous foods Rice Ground meat 
• When I eat bread or pasta, especially if I don’t 
chew it into small pieces, it gets stuck in my upper 
chest / just past throat and I wait 15 - 20 seconds 
for it to pass before I can drink water. It often 
causes tightness in my chest. 
• When I eat carrots, I feel them stick at the top of 
my throat until I wash them down with water. 
• When I eat rice, I have difficulty swallowing or 
sometimes it feels like it gets stuck in my throat. 
• Tightness in my throat when eating hamburgers, 
sandwiches too quickly. Infrequent symptoms.  
• If I eat pasta (wheat) with a thick sauce or lots of 
cheese it feels like a sticky lump in my throat and 
lasts 30+ seconds. 
• Have to peel apples to eat. • When I eat rice and  it is dry it gets stuck so I stay 
away. 
• In the past I have had tightness in my throat while 
eating various things like chicken, hot dogs, steak, 
hamburger, etc. Increases with fluid. Sometimes 
lasts 5 seconds to 10 min or until food passed 
through. 
French Fries Beverages Alcoholic beverages  
• Throat - I can’t swallow pills and certain foods may 
get stuck like French fries. There is no pain. I chew 
my food more than most and can’t drink liquids as 
fast (this is without stretching and medication – 
fluticasone). 
• When I drink diet soda I sometimes get a painful 
lump in my chest - it feels like the liquid gets stuck. 
•  The difficulties swallowing have subsided in the 
past two years and do not currently exist. In the 
past, I had problems when eating rice, meat and 
drinking wine. 
 
• French fries and peanuts are difficult to swallow 
and require water to wash down the food. 
• When I drink liquids quickly, the liquid often 
catches in my throat. 
• Sometimes, when drinking a glass of wine, it feels 
as if my esophagus narrows down. 
 
• Beyond steak and French fries, I can’t identify 
certain foods as being special offenders. 
• Several times per week, even water doesn’t go 
down smoothly. 
• When I eat fast, bread, meat or while drinking 
alcohol, I sometimes get food stuck. 
 
Description, dense / solid Description, dry Description, course / fibrous  
• When I eat certain foods my throat ‘closes’ - 
“clogs” - so that I can’t swallow or eject it. Not 
certain what foods cause this but typically steak or 
heavier meats. Have to wait for clog to subside or 
have emergency treatment. 
• When I eat chicken and it is dry, iIt sticks in my 
throat and I must drink and cough to get it moved.  
• Coarse foods like raw vegetables like carrots, 
broccoli get stuck in my throat, so I avoid them. It 
is very difficult to dislodge food stuck in my throat, 
drinks or coughing don’t work much. 
 
• Also could not eat solid anything for several • When I eat rice and it is dry it gets stuck so I stay • I also could no longer swallow fibrous vegetables,  
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months. avoid it. such as, for example, spinach, beans, celery, etc. 
• If I am off my meds, it feels like food gets caught in 
my throat with dense foods e.g. meats. 
• When I eat dry food (lately corn chips), the food 
sometimes gets hung up in my throat. I have to 
wash it down with water. 
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Supplementary Table 7: Behavioral adaptation to living with dysphagia. 
Strategies avoiding impaction 
Food avoidance Food processing Eating slowly (Trigger, hasty 
eating) Washing food down  
• After 15+ esophageal dilations, I still 
have some problems eating. Always 
have to have water to wash food down. 
Have to chew a lot and still take small 
bites. Certain foods I still stay away 
from. 
• When I eat steak, I have to cut it into 
tiny pieces for fear that it may get stuck 
in my throat. 
• When I eat, at every meal, it doesn’t 
matter what type of food, I notice that 
the food goes down the esophagus 
somewhat slowly. I have to take 
smaller bites, wait until it goes down 
then I can eat again. It takes about 5 
seconds between bites. No pain at all. 
• Always have water with me just in 
case. Have trouble with popcorn, nuts, 
corn, tough meat, thick cheeses, 
bread. Sweets go down easy, except 
caramel – too thick. Have not had 
peanut butter in over 15 years. 
 
• I avoid the steak in pepper and all 
steak for that matter because I feel it is 
tough to swallow.  
• Have to peel apples to eat. • When going out to eat, have to be 
careful what I order, due to eating so 
slow and just being careful on food 
going down. Most of the time, I have to 
take at home half or three quarters of 
the meal because everyone else is 
done. 
• Whenever I eat anything, I always 
have to have something to wash the 
food down. 
 
• When I eat rice and it is dry it gets 
stuck so I avoid it.  
• Eat only foods with sauces, so that I 
can easily swallow them. 
• Always have a drink while eating and 
almost have to eat carefully, slowly. 
• Always have to have water to wash the 
food down. 
 
• Coarse foods like raw vegetables like 
carrots, broccoli get stuck in my throat, 
so I avoid them.  
    
Strategies dealing with impaction 
Choke / cough / vomit impacted 
food out 
Waiting until impaction 
resolves itself 
Washing food down - 
helpful 
Washing food down - not 
helpful  
Other strategies mentioned / 
not specified 
• If coughing and drinking doesn’t 
dislodge food and I can’t swallow my 
saliva, after 10min I panic and will try 
to induce vomiting to dislodge food. 
• When I eat meat or breads, they are 
hard to pass down my esophagus. My 
passage becomes restricted and I am 
forced to wait until the food passes (30 
min - 3 hours) or try to physically throw 
up the blockage. When blockage 
occurs I am subject to spit a lot of 
saliva. 
• My most recent symptom is various 
types of solid foods getting stuck in my 
throat. It will not go down with dry 
swallowing, but will go down with one 
to two drinks of liquid. It happens once 
or twice a week. It will happen even 
with a breath mint that I’ve started to 
chew.  
• When I take pills, they must be very 
small or it will get stuck in throat. 
Nothing like water helps, so I must try 
to throw up the pill.  
• There are times when I will eat 
sandwiches and bites will get stuck for 
about 30 seconds. Repeated 
swallowing and walking tend to help. 
• Periodically meat will remain in my 
esophagus for several minutes and 
coughing or throwing up seem to be 
the only solution. 
• When I eat certain foods my throat 
“closes” - “clogs” - so that I can’t 
swallow or eject it. Not certain what 
foods cause this but typically steak or 
heavier meats. Have to wait for clog to 
subside or have emergency treatment.  
• When eating I use to feel like the food 
would not go all the way down & I had 
to drink something to wash the food 
down. Discomfort ended once food 
was washed down.  
• When I eat items like crackers, 
peanuts, popcorn, etc. - the material 
that’s finely chewed gets stuck in my 
throat. This material is not easily 
washed down with water.  
• Food sticks near my neck, at the base 
of my throat. I have to slap my chest or 
jump up and down to move it. 
• I have had 3 impactions that I now am 
aware of. I felt like I was chocking. My 
throat was tight. After several times 
throwing up, I felt better but was 
unable to eat. Afraid I couldn’t swallow. 
• I have had two total food impactions 
that have had to be removed by 
endoscopy. Both times not even liquids 
would go down and I had to spit up my 
swallowed saliva. Before going to the 
hospital, I tried the Heimlich and 
• When I eat chicken and it is dry. It 
sticks in my throat and must drink and 
cough to get it moved.  
• I have found that sucking on ice works 
better than liquid which can make it 
worse. 
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waited several hours to see if the food 
would go down on its own.  
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Supplementary Table 8: Other themes. 
Allergic reactions related to 
food  Swallowing-associated pain 
Non-swallowing-associated 
pain 
Gastro-esophageal reflux 
disease symptoms 
• When I eat, most foods such as fruits, 
I feel my throat swelling, ears itching, 
throat itching as well.  
• I have trouble swallowing - very, very 
painful and many choking 
experiences.  
• Stomach upset. The pain can last 
several hours. The pain is about a 2 to 
8 [on a 10 point scale] depending on 
the type of food, but it’s annoying. The 
pain may last  half an hour or longer. I 
avoid these foods.  
• I sometimes experience heartburn and 
reflux as a result of the food that I eat. 
• When I eat foods with my specific 
allergen (dairy), or foods that have 
residuals on them, I have trouble 
swallowing, and my throat feels 
swollen shut.   
• When I drink diet soda I sometimes 
get a painful lump in my chest - it 
feels like the liquid gets stuck. It burns 
and is very painful. 
• Prior to be diagnosed I used to get 
severe pain in the middle of my chest 
right at the bottom of my rib cage. The 
pain would last all day and was very 
annoying. Was very hard on me and 
my family. 
• When lying down at bedtime or during 
sleep I am sometimes awakened with 
heartburn, reflux and stomach pain.  
• … many fresh fruits and vegetables 
irritate my mouth, throat and 
stomach…  
• Swallowing non-stick foods gives me 
pain in the chest. 
• A reoccurring chest pain / cramp - 
comes on suddenly. 
• I occasionally have acid reflux, mostly 
at night. 
 • I have chest pain from food blockage 
when I eat the certain foods that block 
my esophagus. Pain is mild but goes 
away once food passes. 
  
Treatment    
Endoscopic desimpaction Dilations Anti-acid/GERD medications 
Swallowed topical 
corticosteroids 
• Three times in the last 10 years I 
have gone to the hospital after many 
attempts at freeing meat - the only 
solution then (after several hours) is 
an upper endoscopy. 
• About a year ago, I had an endoscopy 
and stretching, which helped for a few 
months. 
• Before starting daily pepcid 
[Famotidine],) doses (20mg), I had 
trouble swallowing many types of 
meats and dry foods. Sometimes I 
would have to force the food up, or 
drink water to force the food down. 
• I’m currently using the Fluticasone 
inhaler, so I don’t have any symptoms 
recently. 
• If food does get caught, there is a 
burning where my throat hits my 
stomach. I have been scoped in the 
ER 3x because of this issue. I have 
had 9 total upper GI’s because of this. 
• I have had my throat stretched twice 
in the past. The first time was a piece 
of steak lodged in my throat for 24 
hrs. It was then removed prior to the 
first balloon dilatation. When it was 
lodged, no liquid would pass through.  
• When I used to eat chicken or other 
drier cuts of meat, regardless of the 
size of bite I take on, how much I 
chew it up, I would have difficulty 
swallowing it and need to wash it 
down immediately with water.  Since 
going on an anti-acid reflux regimen, I 
have not experienced this problem 
(only on exceptionally rare occasion). 
• Before I regularly used Flovent 
[fluticasone], I occasionally was unable 
to swallow food - most often, meat - that 
was lodged in my throat. When it 
happened, I often had to go to the 
emergency room to dislodge the food. 
• I have had two total food impactions 
that have had to be removed by 
endoscopy. Both times not even 
liquids would go down and I had to 
spit up my swallowed saliva. 
• After 15+ esophageal dilations, still 
have some problems eating. Always 
have to have water to wash food 
down. Have to chew a lot and still 
take small bites. Certain foods I still 
stay away from. 
• I used to get periodic (i.e. monthly) 
tightness in the center of my chest- a 
stabbing pain. It would last anywhere 
between 5-15 minutes. I have not 
experienced this since taking anti-acid 
medication daily. 
• I can’t swallow pills and certain foods 
may get stuck like French fries. There is 
no pain. I chew my food more than 
most and can’t drink as fast (this is 
without stretchings and medication – 
fluticasone). 
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Supplementary Figure 1: Patient input. 
Supplementary Figure 2: Extract of the survey to gain patient input on EoE-related symptoms. 
Supplementary Figure 3: Conceptual model of the study. 
Supplementary Figure 4: Key domains of EoE-related symptoms. 
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APPENDIX 2: The data obtained from the Visual Dysphagia Question (VDQ) were used to create 
a composite score. The degree of perceived difficulties when eating a given food consistency 
was graded between 0 for ‘No difficulties’ and 3 for ‘Severe difficulties’. These grades for each 
food consistency were summed in the numerator of the score and divided by the maximum sum 
of grades that could be attained for each subject, which depending on the number of food 
consistencies consumed by a subject in a given recall period. 
     For the Avoidance, Modification and Slow Eating (AMS) score, answers to three items 
exploiting the pattern of behavioral adaptation were scored for each food consistency consumed 
by the subject. If patients recorded no behavioral changes, a score of 0 was assigned; when 
reporting eating slower than others, a score of 1 was assigned; when reporting the modification 
of certain food consistencies, a score of 2 was assigned; when reporting both eating slower than 
others and modifying certain food consistencies, a score of 3 was assigned; if the subject 
completely avoided one or several food consistencies due to EoE symptoms, a score of 5 was 
assigned. Scores for all consumed food consistencies were summed up in the numerator and 
divided by the maximum sum of scores that could be attained by a given subject. 
     The VDQ and AMS scores range from 0 to 10.  
    Below we provide a sample calculation of VDQ (A) and AMS (B) scores for a patient X, who 
reported that he/she ate all eight food consistencies and expected to experience moderate 
difficulties eating solid meat, mild difficulties eating dry rice, ground meat and fresh white 
untoasted bread and French fries, and no difficulties eating soft foods, grits/porridge/rice pudding 
and raw fibrous foods. In the past 7 days, the patient reported that he/she modified solid meat 
and French fries, but not other foods. The patient did not avoid any foods. However, the patient 
ate solid meat, ground meat, fresh white untoasted bread and French fries slower than other 
people eating these same foods, but not other foods. The verb ‘modified’ was illustrated with the 
following examples: put the food in the blender, cut it in small pieces, dunk it in liquid or mash it. 
The patient X had a VDQ score of 2.5 and an AMS score of 2. 
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A. VDQ score: 
 
Where: 
1. N1 = number of food consistencies graded with ‘Mild difficulties’ 
2. N2 = number of food consistencies graded with ‘Moderate difficulties’ 
3. N3 = number of food consistencies graded with ‘Severe difficulties’ 
4. D = number of relevant food consistencies (different than ‘Not applicable’) 
 
For patient X, 
N1 = 4 
N2 = 1 
N3 = 0 
D = 8 
 
 
 
B. AMS score: 
 
 
Where: 
1. N1 = number of food consistencies with ‘Yes’ to ‘Eating slowly’ only 
2. N2 = number of food consistencies with ‘Yes’ to ‘Modification’ only 
3. N3 = number of food consistencies with ‘Yes’ to both ‘Eating slowly’ and 
‘Modification’ 
4. N4 = number of food consistencies with ‘Yes’ to ‘Avoidance’ only 
5. D = number of relevant food consistencies (different than ‘Not applicable’) 
 
For patient X, 
N1 = 2 (ground meat and fresh white untoasted bread) 
N2 = 0 
N3 = 2 (solid meat and French fries) 
N4 = 0 
D = 8 
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APPENDIX 3: SUPPLEMENTARY TABLES AND FIGURES. 
 
Supplementary Table 9: Description of the physician and histology instruments. 
 Physician instrument Histology instrument 
Derivation Delphi Delphi 
Completed 
by 
Physician and study coordinator (if 
applicable) Pathologist 
Number of 
items 39 close-ended items 22 close-ended items 
Type of items 
5 items: dichotomous scale 
1 item: Likert scale 
21 items: multiple non-hierarchical 
options 
12 items: multiple hierarchical 
options 
3 items: dichotomous scale 
0 items: Likert scale 
13 items: multiple non-hierarchical 
options 
6 items use multiple hierarchical 
options 
Average 
completion 
time 
30 minutes 10 minutes (without histologic 
evaluation) 
Overall 
assessment 
variable 
Physician global assessment of 
EoE activity (11-point Likert scale)  
Domains 1. EoE treatment strategies 
a. treatment with steroids 
b. elimination diets 
c. dilation 
2. Blood biomarkers 
a. eosinophil serum levels 
b. IgE 
c. IL-5 
3. Endoscopic features 
a. endoscopic features described 
by Hirano et al.34 with some 
modifications 
4. GERD 
a. presence of GERD 
b. GERD-like symptoms 
c. Barrett’s esophagus 
d. hiatal herniation 
e. fundoplication surgery 
5. General 
a. qualification and experience of 
the participating 
gastroenterologists 
1. Distal esophagus 
a. eosinophil peak number  
b. distribution of eosinophils in a 
high power field 
c. percentage of high power field 
covered by the tissue 
d. sample orientation 
e. distribution of inflammation 
f. presence of abscesses 
g. basal layer enlargement 
h. lamina propria fibrosis 
2. Proximal esophagus 
same as above 
3. General 
a. qualification and experience of 
the participating pathologist  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Schoepfer AM, et al. EEsAI PRO Instrument. Supplementary material. Page 27 of 28 
 
Supplementary Table 10: Symptom severity and behavioral changes when eating foods of eight distinct consistencies as assessed by the visual 
dysphagia question (n = 153). 
Characteristic Solid meat Ground meat Fresh bread Dry rice Raw food French fries Grits, porridge Soft foods 
  
No. % No. % No. % No. % No. % No. % No. % No. % 
Difficulties eating                 
No 37 24.2 81 52.9 69 45.1 69 45.1 85 55.6 89 58.2 127 83.0 141 92.2 
Mild 56 36.6 37 24.2 45 29.4 52 34.0 39 25.5 39 25.5 13 8.5 6 3.9 
Moderate 39 25.5 26 17.0 24 15.7 22 14.4 16 10.5 11 7.2 2 1.3 1 0.7 
Severe 21 13.7 8 5.2 8 5.2 8 5.2 11 7.2 8 5.2 6 3.9 5 3.3 
Don't know 0 0.0 0 0.0 6 3.9 1 0.7 1 0.7 4 2.6 4 2.6 0 0.0 
Missing 0 0.0 1 0.7 1 0.7 1 0.7 1 0.7 2 1.3 1 0.7 0 0.0 
Behavior                 
Modification 23 15.0 6 3.9 7 4.6 5 3.3 10 6.5 7 4.6 0 0.0 1 0.7 
Avoidance 17 11.1 13 8.5 11 7.2 16 10.5 18 11.8 7 4.6 5 3.3 1 0.7 
Eating slower 103 67.3 65 42.5 54 35.3 51 33.3 47 30.7 36 23.5 9 5.9 8 5.2 
The eight food consistencies and examples of foods to illustrate those are as follows: 1) solid meat (steak, chicken, turkey lamb), 2) soft foods (pudding, jelly, apple 
sauce), 3) dry rice or sticky Asian rice, 4) ground meat (hamburger, meatloaf), 5) fresh white untoasted bread or similar foods (doughnut, muffin, cake), 6) grits, 
porridge (oatmeal), or rice pudding, 7) raw fibrous foods (apple, carrot, celery) 8) French fries. The sample calculation of the visual dysphagia question and food 
avoidance, modification and slow eating scores are provided in Appendix 2. 
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Supplementary Figure 5: Timetable for the adult EEsAI study. 
 
Supplementary Figure 6: This figure illustrates the relationship between the Patient Global 
Assessment of EoE severity and the PRO components that were chosen for the construction of 
the PRO score. The data for 7-day recall period are shown. Abbreviations: TS, trouble 
swallowing. 
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